Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria

Lipoglycopeptide antibiotics are semi-synthetic derivatives of glycopeptides and are characterized by a pronounced bactericidal activity against gram-positive pathogens. The aim of the study was comparative assessment of the sensitivity of gram-positive clinical isolates to lipoglycopeptide antibiot...

Full description

Saved in:
Bibliographic Details
Main Authors: V. V. Gostev, O. S. Sulian, O. S. Kalinogorskaya, L. N. Popenko, A. N. Kruglov, S. A. Gordeeva, E. V. Nesterova, D. P. Gladin, N. N. Trophimova, P. S. Chulkova, I. V. Ageevets, V. A. Ageevets, T. V. Chernenkaya
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2022-12-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/964
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849403861260828672
author V. V. Gostev
O. S. Sulian
O. S. Kalinogorskaya
L. N. Popenko
A. N. Kruglov
S. A. Gordeeva
E. V. Nesterova
D. P. Gladin
N. N. Trophimova
P. S. Chulkova
I. V. Ageevets
V. A. Ageevets
T. V. Chernenkaya
author_facet V. V. Gostev
O. S. Sulian
O. S. Kalinogorskaya
L. N. Popenko
A. N. Kruglov
S. A. Gordeeva
E. V. Nesterova
D. P. Gladin
N. N. Trophimova
P. S. Chulkova
I. V. Ageevets
V. A. Ageevets
T. V. Chernenkaya
author_sort V. V. Gostev
collection DOAJ
description Lipoglycopeptide antibiotics are semi-synthetic derivatives of glycopeptides and are characterized by a pronounced bactericidal activity against gram-positive pathogens. The aim of the study was comparative assessment of the sensitivity of gram-positive clinical isolates to lipoglycopeptide antibiotics (telavancin, dalbavancin, oritavancin). The following isolates were included in the work: methicillin-resistant Staphylococcus aureus (MRSA, n=780), methicillin-resistant coagulase-negative Staphylococcus spp. (MRCoNS, n=163), and vancomycin-resistant Enterococcus faecium (VREf, n=93). Serial dilutions were used to assess sensitivity with the addition of 0.002% polysorbate 80 to the medium. Lipoglycopeptides showed more pronounced antibacterial activity against MRSA compared to vancomycin, teicoplanin, and daptomycin, and had a MIC₅₀/MIC₉₀ (µg/ml): for telavancin — 0.06 /0.125, for dalbavancin — 0.016/0.06, and for oritavancin — 0.06/0.125. A trend towards an increase in the MIC of lipoglycopeptides and daptomycin was established in MRSA with the MIC of 2 µg/ml for vancomycin, the proportion of which was 13%. For MRCoNS, MIC₅₀ and MIC₉₀ of lipoglycopeptides did not exceed 0.06 µg/ml and 0.125 µg/ml, respectively. Oritavancin showed strong activity against VREf at MIC range of 0.03 µg/ml to 0.5 µg/ml, and at MIC₉₀ of 0.25 µg/ml. Thus, lipoglycopeptide antibiotics are a plausible alternative to vancomycin and daptomycin; they are characterized by pronounced activity and can be used to treat severe forms of staphylococcal infections.
format Article
id doaj-art-99846c741b494c3da9f489092cfa00d6
institution Kabale University
issn 0235-2990
language Russian
publishDate 2022-12-01
publisher LLC "Publishing House OKI"
record_format Article
series Антибиотики и Химиотерапия
spelling doaj-art-99846c741b494c3da9f489092cfa00d62025-08-20T03:37:09ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902022-12-01679-10182410.37489/0235-2990-2022-67-9-10-18-24867Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive BacteriaV. V. Gostev0O. S. Sulian1O. S. Kalinogorskaya2L. N. Popenko3A. N. Kruglov4S. A. Gordeeva5E. V. Nesterova6D. P. Gladin7N. N. Trophimova8P. S. Chulkova9I. V. Ageevets10V. A. Ageevets11T. V. Chernenkaya12Pediatric Research and Clinical Center for Infectious Diseases; North-Western State Medical University Named after I. I. MechnikovPediatric Research and Clinical Center for Infectious DiseasesPediatric Research and Clinical Center for Infectious DiseasesSt. Petersburg I. I. Dzhanelidze Research Institute of Emergency MedicineMoscow Multidisciplinary Clinical Center «Kommunarka»Clinical Infectious Diseases Hospital named after S.P. BotkinCity Skin and Venereal Diseases DispensarySt. Petersburg State Pediatric Medical University of the Ministry of Health of the Russian FederationCity Skin and Venereal Diseases DispensaryPediatric Research and Clinical Center for Infectious DiseasesPediatric Research and Clinical Center for Infectious DiseasesPediatric Research and Clinical Center for Infectious DiseasesN.V. Sklifosovsky Research Institute for Emergency MedicineLipoglycopeptide antibiotics are semi-synthetic derivatives of glycopeptides and are characterized by a pronounced bactericidal activity against gram-positive pathogens. The aim of the study was comparative assessment of the sensitivity of gram-positive clinical isolates to lipoglycopeptide antibiotics (telavancin, dalbavancin, oritavancin). The following isolates were included in the work: methicillin-resistant Staphylococcus aureus (MRSA, n=780), methicillin-resistant coagulase-negative Staphylococcus spp. (MRCoNS, n=163), and vancomycin-resistant Enterococcus faecium (VREf, n=93). Serial dilutions were used to assess sensitivity with the addition of 0.002% polysorbate 80 to the medium. Lipoglycopeptides showed more pronounced antibacterial activity against MRSA compared to vancomycin, teicoplanin, and daptomycin, and had a MIC₅₀/MIC₉₀ (µg/ml): for telavancin — 0.06 /0.125, for dalbavancin — 0.016/0.06, and for oritavancin — 0.06/0.125. A trend towards an increase in the MIC of lipoglycopeptides and daptomycin was established in MRSA with the MIC of 2 µg/ml for vancomycin, the proportion of which was 13%. For MRCoNS, MIC₅₀ and MIC₉₀ of lipoglycopeptides did not exceed 0.06 µg/ml and 0.125 µg/ml, respectively. Oritavancin showed strong activity against VREf at MIC range of 0.03 µg/ml to 0.5 µg/ml, and at MIC₉₀ of 0.25 µg/ml. Thus, lipoglycopeptide antibiotics are a plausible alternative to vancomycin and daptomycin; they are characterized by pronounced activity and can be used to treat severe forms of staphylococcal infections.https://www.antibiotics-chemotherapy.ru/jour/article/view/964staphylococcus aureusmrsastaphylococcienterococcisensitivityvancomycintelavancinoritavancindalbavancinteicoplanindaptomycin
spellingShingle V. V. Gostev
O. S. Sulian
O. S. Kalinogorskaya
L. N. Popenko
A. N. Kruglov
S. A. Gordeeva
E. V. Nesterova
D. P. Gladin
N. N. Trophimova
P. S. Chulkova
I. V. Ageevets
V. A. Ageevets
T. V. Chernenkaya
Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria
Антибиотики и Химиотерапия
staphylococcus aureus
mrsa
staphylococci
enterococci
sensitivity
vancomycin
telavancin
oritavancin
dalbavancin
teicoplanin
daptomycin
title Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria
title_full Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria
title_fullStr Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria
title_full_unstemmed Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria
title_short Comparative Activity of Lipoglycopeptide Antibiotics Against Gram-Positive Bacteria
title_sort comparative activity of lipoglycopeptide antibiotics against gram positive bacteria
topic staphylococcus aureus
mrsa
staphylococci
enterococci
sensitivity
vancomycin
telavancin
oritavancin
dalbavancin
teicoplanin
daptomycin
url https://www.antibiotics-chemotherapy.ru/jour/article/view/964
work_keys_str_mv AT vvgostev comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT ossulian comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT oskalinogorskaya comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT lnpopenko comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT ankruglov comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT sagordeeva comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT evnesterova comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT dpgladin comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT nntrophimova comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT pschulkova comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT ivageevets comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT vaageevets comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria
AT tvchernenkaya comparativeactivityoflipoglycopeptideantibioticsagainstgrampositivebacteria